An Empirical Analysis on the European Market of Human Experimentation
Roberto Ippoliti ()
IEL Working Papers from Institute of Public Policy and Public Choice - POLIS
The target of this work is to support the thesis that pharmaceutical companies' testing phase would be treated like any other form of production in a globalization process, that is to say, a specific phase of pharmaceutical R&D could be localized where the cost of clinical evidence is lower. Considering Europe, an empirical analysis in order to support the main hypothesis is performed. Taking trials of phases II and III, funded by Industry (dependent variable) and the main macroeconomic features (independent variables) of each nation into account, the empirical work is implemented via regression analysis on panel data (2000 - 2007). The sample analyzed considers EU-27 plus the candidate states (Croatia, the Former Yugoslav Republic of Macedonia, Turkey), Norway, Switzerland and Iceland. Results suggest the appropriateness of this process since clinical research is clearly affected by economic conditions, regardless of the scientific purpose.
Keywords: Pharmaceutical Company R&D; Human experimentation; Medical Researcher; Research Subject (search for similar items in EconPapers)
JEL-codes: I11 (search for similar items in EconPapers)
New Economics Papers: this item is included in nep-eur and nep-ino
References: Add references at CitEc
Citations Track citations by RSS feed
Downloads: (external link)
This item may be available elsewhere in EconPapers: Search for items with the same title.
Export reference: BibTeX
RIS (EndNote, ProCite, RefMan)
Persistent link: https://EconPapers.repec.org/RePEc:uca:ucaiel:7
Access Statistics for this paper
More papers in IEL Working Papers from Institute of Public Policy and Public Choice - POLIS
Series data maintained by Lucia Padovani ().